Drugs / AMG 228
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02437916 | Apr 2015 → Dec 2016 | bladder transitional cell carcinoma, colorectal cancer, head and neck squamous cell carcinoma, melanoma +1 | Amgen | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02437916 ↗ |
| Route | Intravenous | “AMG 228 will be administered intravenously” NCT02437916 ↗ |